Modern strategies of STEMI/NSTEMI management, that include revascularization by coronary stenting, bypass grafting, nowadays are used in 30-40% of urgent patients of such category. The prevalent part of patients is treated by administration of the optimal drug therapy.
The objective of the research was to study the influence of adenosine-5-triphosphogluconate-magnesium trisodium salt and levocarnitine on the clinical course of STEMI/NSTEMI.
Materials and methods. 100 patients with STEMI/NSTEMI were included into the research. Depending on the therapy scheme, patients were divided into three groups and the control one. Determination of the key parameters was performed initially after hospitalization and at the day of patient discharge.
Results. Promising results were shown while slowing the myocardial fibrosing. Limiting of the infarcted and `stunned` myocardium area resulted in ejection fraction increase, increase of the myocardial reserve, measured by echocardiographic indexes.
Conclusions. Decreasing of myocardial fibrosing can be potentiated by the pharmacological postconditioning as well as limiting of the necrotic myocardium area and increase of viable myocardium area. Pharmacological postconditioning is effective and save, that can be proved by the absence of any serious complications.
Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. New England Journal of Medicine. 2007; 357: 1121-35. DOI: https://doi.org/10.1056/NEJMra071667 [PMid:17855673]
Heusch G, Libby P, Gersh B, et al. Cardiovascular remodeling in coronary artery disease and heart failure. The Lancet.2014;383:1933-43. DOI: https://doi.org/10.1016/S0140-6736(14)60107-0
Bulluck H, et al. Reducing myocardial infarct size: challenges and future opportunities. Heart Journal.2016;102:341-348. DOI: https://doi.org/10.1136/heartjnl-2015-307855 [PMid:26674987 PMCid:PMC4789695]
Ratmanova A. Myocardial preconditioning: natural mechanisms of cardioprotection in normal and pathological states. Medicine Review.2008;3(3):27-35.
Haskо G, Linden J, Cronstein B, Pacher P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nature Reviews Drug Discovery. 2008;7:759-770. DOI: https://doi.org/10.1038/nrd2638 [PMid:18758473 PMCid:PMC2568887]
Oyanagi E, Yano H, Uchida M, Utsumi K, Sasaki J. Protective action of l-carnitine on cardiac mitochondrial function and structure against fatty acid stress. Biochemical and Biophysical Research Communications. 2011; 412: 61-67. DOI: https://doi.org/10.1016/j.bbrc.2011.07.039 [PMid:21791201]
Şıktar E, Ekinci D, Şıktar E, Beydemir S, Gülçin I, Günay M. Pro-tective role of L-carnitine supplementation against exhaustive exercise induced oxidative stress in rats. European Journal of Pharmacology. 2011; 668:407-413. DOI: https://doi.org/10.1016/j.ejphar.2011.07.032 [PMid:21839078]
Mishchenko L. Role of inosine, l-arginine and l-carnitine in cardiomethabolic therapy. Ukraine Health.2018;11-12(432-433):21.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.